Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinica BavieraXMAD:CBAV -0.70%100 Cash-to-Debt is 5.21 as of Jun. 2026, which is 614% above its 10-year median of 0.73. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €44.74 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 72.12% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Clinica Baviera's cash to debt ratio for the quarter that ended in Jun. 2026 was 5.21.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Clinica Bavieracould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Clinica Baviera's Cash-to-Debt or its related term are showing as below:
XMAD:CBAV'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12 Med: 0.73 Max: 32.62
Current: 5.21
During the past 13 years, Clinica Baviera's highest Cash to Debt Ratio was 32.62. The lowest was 0.12. And the median was 0.73.
XMAD:CBAV's Cash-to-Debt is ranked better than 72.12% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.98
vs XMAD:CBAV: 5.21
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Clinica Baviera Cash-to-Debt Related Terms
Clinica Baviera Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XMAD:CBAV vs TMO, DHR, NTRA: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera (XMAD:CBAV) has a Cash-to-Debt of 5.21 as of Jun. 2026. This is 614% above median its historical median of 0.73. Over the past decade, Clinica Baviera's Cash-to-Debt has ranged from 0.12 to 32.62. According to the industry distribution chart, Clinica Baviera ranks #58 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 27.9%.
Is Clinica Baviera's Cash-to-Debt too high?
Clinica Baviera's current Cash-to-Debt of 5.21 is 614% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 32.62. The Medical Diagnostics & Research industry median Cash-to-Debt is 0.98. Clinica Baviera's value of 5.21 is 431.6% above this industry median. Based on the distribution chart, Clinica Baviera ranks #58 out of 208 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #58 out of 208 companies for Cash-to-Debt. This puts Clinica Baviera in the upper half of its industry. The industry median Cash-to-Debt is 0.98. Clinica Baviera's value of 5.21 is 431.6% above this benchmark. Historically, Clinica Baviera's own Cash-to-Debt has ranged from 0.12 to 32.62 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 0.98, Clinica Baviera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 0.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current Cash-to-Debt of 5.21 is 431.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current Cash-to-Debt is 5.21, which is 614% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Modestly Overvalued. The stock's GF Value™ is €44.74, compared to a current price of €56.40 — trading 26.1% above its estimated fair value. The current Cash-to-Debt is 5.21, which is 614% above median its 10-year median of 0.73 and 431.6% above the Medical Diagnostics & Research industry median of 0.98. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current Cash-to-Debt is 5.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.40 is trading 26.1% above its estimated GF Value™ of €44.74.
GuruFocus considers Clinica Baviera to be Modestly Overvalued.
Key valuation signals for XMAD:CBAV:
Cash-to-Debt: 5.21 (614% above median its 10-year median of 0.73)
GF Value™: €44.74 vs. price of €56.40 (26.1% above fair value)
Industry Position: 431.6% above the Medical Diagnostics & Research median (#58 of 208)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
